Search results for "alpha-Fetoproteins"

showing 7 items of 37 documents

The nucleotide and deduced amino acid structures of sheep and pig fetuin. Common structural features of the mammalian fetuin family

1992

This study was initiated to gain further insight into the structural features of the mammalian fetuin family. The cDNA structures of sheep and pig fetuin were determined. The cDNA insert encoding sheep (pig) fetuin comprised 1550 (1470) nucleotides, including 54 (46) nucleotides encoding a signal peptide of 18 (15) residues and 1038 (1041) nucleotides encoding the 346 (347) amino acids of the mature plasma protein. The predicted amino-terminal sequence of the mature pig fetuin was confirmed by the amino-terminal sequence of the purified protein. However, two alternative sheep amino-terminal sequences were found in fetuin purified from the plasma of a single sheep fetus; the minor product wa…

Signal peptideGlycosylationSwineBlotting WesternMolecular Sequence DataSequence alignmentBiologyBiochemistrySequence Homology Nucleic AcidComplementary DNAEndopeptidasesAnimalsHumansAmino Acid SequenceCloning MolecularPeptide sequenceMammalschemistry.chemical_classificationSheepBase SequenceSerine EndopeptidasesStructural geneNucleic acid sequenceMembrane ProteinsDNAMolecular biologyFetuinAmino acidBiochemistrychemistryElectrophoresis Polyacrylamide Gelalpha-FetoproteinsEuropean Journal of Biochemistry
researchProduct

Recurrence of hepatocellular carcinoma after liver transplantation: an update.

2015

Liver transplantation is the only curative alternative for selected patients with hepatocellular carcinoma (HCC) who are not eligible for resection and/or with decompensated cirrhosis. According to Milan criteria the 5-year survival rate is 70–85%, with a recurrence-free survival of 75%. However, HCC recurrence rate after liver transplantation remains a significant problem in the clinical practice. The prognosis in patients with HCC recurrence is poor. The treatment of choice for HCC recurrence is surgery, but it seems that a systemic treatment based on combination of an mTOR inhibitor with sorafenib can be used. Data on safety and efficacy are limited, clinical monitoring is necessary. Th…

SorafenibOncologyCancer Researchmedicine.medical_specialtyrecurrenceCarcinoma Hepatocellularmedicine.medical_treatmentliving donorLiver transplantationMilan criteriaGastroenterologyLeukocyte CountRisk FactorsInternal medicinemedicineBiomarkers TumorCombined Modality TherapyHumansalpha-FetoproteinPerioperative PeriodSurvival rateimmunosuppressionbusiness.industryRisk FactorLiver NeoplasmsImmunosuppressionGeneral MedicinePerioperativehepatocellular carcinomamedicine.diseaseCombined Modality Therapydigestive system diseasesLiver TransplantationTumor BurdenOncologyLiver NeoplasmHepatocellular carcinomaalpha-FetoproteinsNeoplasm Recurrence Localbusinessmedicine.drugHumanFuture oncology (London, England)
researchProduct

Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.

2020

Background & Aims: Limited data on treatment of elderly patients with hepatocellular carcinoma (HCC) increase the unmet need. REACH and REACH-2 were global phase III studies of ramucirumab in patients with HCC after prior sorafenib, where patients with alpha-fetoprotein (AFP) ≥400 ng/mL showed an overall ssurvival (OS) benefit for ramucirumab. These post-hoc analyses examined efficacy and safety of ramucirumab in patients with HCC and baseline AFP ≥ 400 ng/mL by three prespecified age subgroups (<65, ≥65 to <75 and ≥75 years). Methods: Individual patient data were pooled from REACH (baseline AFP ≥400 ng/mL) and REACH-2. Kaplan-Meier and Cox proportional hazards regression methods …

Sorafenibmedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinoma[SDV.CAN]Life Sciences [q-bio]/CancerSorafenib intolerancePlaceboAntibodies Monoclonal HumanizedGastroenterologyRamucirumabRamucirumabCàncer de fetge03 medical and health sciences0302 clinical medicineElderlyInternal medicineCox proportional hazards regressionMedicineHumansAgedHepatologyElevated alpha-fetoproteinbusiness.industryPersones grans dependentsHazard ratioLiver Neoplasms[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyHepatitis CSorafenibmedicine.diseaseFrail elderly3. Good healthVEGFR2Treatment Outcome030220 oncology & carcinogenesisHepatocellular carcinoma[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology030211 gastroenterology & hepatologyMonoclonal antibodiesAlpha-fetoprotein (AFP)alpha-FetoproteinsbusinessAnticossos monoclonalsLiver cancermedicine.drugLiver international : official journal of the International Association for the Study of the LiverREFERENCES
researchProduct

Cloning and Targeted Deletion of the Mouse Fetuin Gene

1998

We proposed that the alpha2-Heremans Schmid glycoprotein/fetuin family of serum proteins inhibits unwanted mineralization. To test this hypothesis in animals, we cloned the mouse fetuin gene and generated mice lacking fetuin. The gene consists of seven exons and six introns. The cystatin-like domains D1 and D2 of mouse fetuin are encoded by three exons each, whereas a single terminal exon encodes the carboxyl-terminal domain D3. The promoter structure is well conserved between rat and mouse fetuin genes within the regions shown to bind transcription factors in the rat system. Expression studies demonstrated that mice homozygous for the gene deletion lacked fetuin protein and that mice heter…

alpha-2-HS-GlycoproteinMolecular Sequence DataBiologyBiochemistryMiceEctopic calcificationExonCalcification PhysiologicApatitesmedicineAnimalsCloning MolecularPromoter Regions GeneticMolecular BiologyGeneMice Knockoutchemistry.chemical_classificationBase SequenceIntronBlood ProteinsSequence Analysis DNACell Biologymedicine.diseaseNull alleleMolecular biologyFetuinRatschemistryFemalealpha-FetoproteinsGlycoproteinalpha-2-HS-glycoproteinGene DeletionJournal of Biological Chemistry
researchProduct

Rat tyrosine kinase inhibitor shows sequence similarity to human α2-HS glycoprotein and bovine fetuin

1991

Human alpha 2-HS glycoprotein and bovine fetuin, abundant proteins of fetal plasma, are structural members of the fetuin family within the cystatin superfamily. They are characterized by the presence of two N-terminally located cystatin-like units and a unique C-terminal sequence segment not present in the other members of the cystatin superfamily. Search for related sequences revealed that the natural inhibitor of the insulin receptor tyrosine kinase [Auberger, Falquerho, Contreres, Pages, Le Cam, Rossi & Le Cam (1989) Cell (Cambridge, Mass.) 58, 631-640] shows sequence similarity to the mammalian fetuins. The sequence identity between rat tyrosine kinase inhibitor, human alpha 2-HS gl…

alpha-2-HS-Glycoproteinmedicine.drug_classMolecular Sequence DataBiochemistryTyrosine-kinase inhibitorReceptor tyrosine kinaseHomology (biology)Protein structureSequence Homology Nucleic AcidmedicineAnimalsHumansAmino Acid SequenceMolecular Biologychemistry.chemical_classificationbiologyBlood ProteinsCell BiologyProtein-Tyrosine KinasesMolecular biologyFetuinRatschemistryBiochemistrybiology.proteinCattlealpha-FetoproteinsGlycoproteinSequence Alignmentalpha-2-HS-glycoproteinResearch ArticleCysteineBiochemical Journal
researchProduct

Posttranslational processing of human alpha 2-HS glycoprotein (human fetuin). Evidence for the production of a phosphorylated single-chain form by he…

1994

alpha 2-HS glycoprotein (alpha 2-HS) is a major protein occurring in human blood and calciferous tissues. Due to extensive sequence identity, alpha 2-HS has been grouped with the fetuins, a family of proteins that occur in fetal plasma in high concentrations. Native alpha 2-HS undergoes a series of posttranslational modifications including proteolytic processing, multiple N-glycosylations and O-glycosylations, and sulfation of the carbohydrate side chains. Various two-chain forms of alpha 2-HS have been prepared from human plasma, however, the single-chain precursor has not yet been isolated. Here, we have studied the biosynthesis of alpha 2-HS by a human hepatoma cell line, HepG2. We demon…

chemistry.chemical_classificationCarcinoma HepatocellularGlycosylationLiver NeoplasmsMolecular Sequence DataAlpha (ethology)PeptideBiologyBiochemistryFetuinSerineSulfationchemistryBiochemistryTumor Cells CulturedPhosphorylationHumansAmino Acid Sequencealpha-FetoproteinsPhosphorylationGlycoproteinPeptide sequenceProtein Processing Post-TranslationalEuropean journal of biochemistry
researchProduct

GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis

2020

Background & Aims The prevalence of nonalcoholic steatohepatitis (NASH) associated hepatocellular carcinoma (HCC) is increasing. However, strategies for detection of early-stage HCC in patients with NASH have limitations. We assessed the ability of the GALAD score, which determines risk of HCC based on patient sex; age; and serum levels of α-fetoprotein (AFP), AFP isoform L3 (AFP-L3), and des-gamma-carboxy prothrombin (DCP), to detect HCC in patients with NASH. Methods We performed a case-control study of 125 patients with HCC (20% within Milan Criteria) and 231 patients without HCC (NASH controls) from 8 centers in Germany. We compared the performance of serum AFP, AFP-L3, or DCP vs GALAD …

medicine.medical_specialtyCirrhosisCarcinoma HepatocellularMedizinPilot ProjectsMilan criteriaGastroenterologySensitivity and SpecificityCohort Studies03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicinemedicineBiomarkers TumorHumansProtein PrecursorsneoplasmsHepatologyReceiver operating characteristicbusiness.industryLiver NeoplasmsGastroenterologyArea under the curvemedicine.diseasedigestive system diseasesROC Curve030220 oncology & carcinogenesisHepatocellular carcinomaCase-Control StudiesCohort030211 gastroenterology & hepatologyProthrombinalpha-FetoproteinsbusinessLiver cancerBiomarkersCohort study
researchProduct